Conditions: Ankylosing Spondylitis
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 84
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402)(NCT00247962) study.

Detailed description:

Arms:
arm 1: Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.

Interventions: intervention 1: Enbrel (etanercept)
Intervention descriptions: intervention 1: Etanercept 50 mg SC injection once weekly

Protocol document: